Tofersen (Qalsody) is a 20-mer ASO gapmer with mixed PS/PO linkages, approved to treat amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutation in 2023 (Table 2) (U.S. Food and Drug Administration, 2023b). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.